Brief intro:
- Author: Wei Feng, Julijus Bogomolovas, Abraham Grant Shain, Li Wang, Chao Chen, Mao Ye, Yusu Gu, Xiaohai Zhou, Ju Chen
- Journal: Circulation
- Doi: https://www.doi.org/10.1161/CIRCULATIONAHA.125.074632
- Publication Date: 2025/11/19
Abstract
ALPK3 (alpha protein kinase 3) is characterized by its unique alpha kinase domain and is localized to the M band in cardiomyocytes to maintain sarcomere integrity, functioning as a pseudokinase1,2. Individuals harboring homozygous or compound heterozygous loss-of-function ALPK3 mutations present severe cardiomyopathy at birth, or in early childhood3. Heterozygous ALPK3 variants are associated with adult hypertrophic cardiomyopathy4. Consequently, restoring ALPK3 expression emerges as a promising approach for treating cardiomyopathy resulting from ALPK3 deficiency.
In exploring therapeutic strategies, we attempted to use the adeno-associated virus (AAV) vector to deliver full-length Alpk3 cDNA to cardiomyocytes in global Alpk3 knockout (Alpk3−/−) mice. These mice recapitulate the clinical manifestations of cardiomyopathies in human patients with homozygous loss-of-function ALPK3 mutations and provide a reliable model for studying ALPK3-associated cardiomyopathies1,4. All animal procedures adhered to institutional guidelines and received approval from the Institutional Animal Care and Use Committee (IACUC). However, the full-length Alpk3 coding region spans 5,040 bp, which exceeds the AAV packaging limit of 4.7 kb. ALPK3 is encoded by 14 exons, with exon 6 alone contributing to 40% of the coding sequence. Given that this region is predicted to be intrinsically disordered by in silico disorder prediction tools, we sought to generate a truncated version of ALPK3 through an in-frame deletion of a large portion of exon 6, with the goal of preserving protein functionality. Using CRISPR-Cas9, we successfully removed a 1,119 bp segment from exon 6 to create a miniALPK3 variant (Figure A). Sequencing confirmed the deletion of amino acids in exon 6 (Figure B). Mice homozygous for miniALPK3 exhibited normal cardiac function for up to 15 months of age (Figure C), demonstrating that miniALPK3 retains the functional properties of the full-length protein in the heart.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.